While localized disease can be effectively treated surgically, half of all patients develop metastasis, and metastatic UM carries a dismal prognosis with an overall survival of only 6 months (Diener- West et al., 2005) . Approximately half of the patients harbor metastases to multiple organs, with liver (93%), lung (24%), bone (16%), and lymph nodes (10%) representing the most common sites (Collaborative Ocular Melanoma Study Group, 2001 ).
Over the past decade, we have gained considerable insight into the genetic basis of UM. This has not yet led to novel therapeutic options and there are still no proven systemic treatments for UM. UM is highly distinct from cutaneous melanoma (CM) both clinically and molecularly. UM is not associated with sun exposure and has among the lowest mutation rates in cancer, whereas CM has among the highest mutation rates due to UV damage (Furney et al., 2013) . A recent comparison of liver metastasis revealed that most CM metastases lacked gross melanin pigmentation while most UM metastases are hyperpigmented and express high levels of melanocyte lineage proteins, such as MART-1 (MLANA) and gp100 (PMEL) (Rothermel et al., 2016) . Molecularly, CM is driven by recurrent somatic mutations that activate the mitogen-activated protein kinase (MAPK) pathway, including BRAF, NRAS, NF1, and KIT. Approximately 90% of UMs harbor activating mutations in two homologous G-protein alpha (Ga) subunits, GNA11 (Ga 11 ) and GNAQ (Ga q ), at codons Gln209 or Arg183 (Robertson et al., 2017; Van Raamsdonk et al., 2009 . Among the remaining 10% of UMs, most harbor activating mutations in a G-protein-coupled receptor (CYSLTR2 at the Leu129 codon activates Ga 11/q ) or in phospholipase C b4 (PLCB4) (at the Asp630 codon, a direct downstream effector of Ga 11/q cleaves phosphatidylinositol 4,5-bisphosphate [PIP 2 ] to produce the second messengers diacylglycerol [DAG] and inositol triphosphate [IP 3 ] (Johansson et al., 2016; Moore et al., 2016) . This indicates a requirement for Ga 11/q -coupled signaling and, in particular, the phospholipase Cb (PLCb) effector pathway in the initiation of UMs.
While essentially all UMs harbor mutations in the CYSLTR2-Ga 11/q -PLCb pathway, the prognosis is largely determined by the presence of cooperative mutations. Monosomy 3 and an associated poor-prognosis gene expression pattern is the single most negative prognostic factor. Most of these tumors harbor inactivating mutations in BAP1, located at 3q21, and essentially all of these tumors lose expression of the BAP1 protein, implicating BAP1 loss as a critical cooperating lesion driving poor prognosis in UM (Harbour et al., 2010; Robertson et al., 2017) . Among tumors with disomy 3, there are mutually exclusive mutations in SF3B1, associated with intermediate prognosis, and in EIF1AX, associated with favorable prognosis (Martin et al., 2013; Robertson et al., 2017) .
In addition to UM, CYSLTR2-Ga 11/q -PLCb pathway mutations are found in most leptomeningeal melanocytic neoplasms (LMNs) and blue nevi Van Raamsdonk et al., 2009 ). LMNs are rare neoplasms arising from melanocytes of the leptomeninges. Like UM, in addition to mutations in GNA11 and GNAQ, LMNs harbor mutually exclusive comutations in either EIF1AX or SF3B1 in 33% of cases (K€ usters-Vandevelde et al., 2016) . Blue nevi are common benign neoplasms of dermal melanocytes, which are distinguished from CMs that arise from epidermal melanocytes. Rare malignant melanomas that either arise from blue nevi or show morphologic features of blue nevi are called malignant blue nevi. Recent genetic characterization of a large cohort of blue nevi showed both benign and malignant blue nevi harbored CYSLTR2-Ga 11/q -PLCb pathway mutations . EIF1AX mutations are found only in benign blue nevi, while SF3B1 and BAP1 mutations are found only in malignant blue nevi (Griewank et al., 2017) . Therefore, UM, LMN, and blue nevi represent a molecularly similar spectrum of diseases that commonly harbor CYSLTR2-Ga 11/q -PLCb mutations and whose disease aggressiveness is defined by co-mutations, especially BAP1.
Because the PLCb pathway is known to activate MAPK, the MEK inhibitor selumetinib has been clinically studied. While a phase 2 trial showed promising improvement in progressionfree survival, the phase 3 trial failed to confirm the finding and neither trial showed an improvement in overall survival (Carvajal et al., 2014; Komatsubara et al., 2016) . As different MEK inhibitors have distinct properties (Lito et al., 2014) , it is still currently unclear whether the MAPK pathway remains a viable therapeutic target in UM.
To identify molecular and lineage events downstream of Ga 11 activation, the cooperative role of BAP1 loss, and critical nodes required for Ga 11 -mediated tumorigenesis, we generated a conditional Rosa26-LSL-GNA11 Q209L mouse model and crossed it with conditional Bap1 knockout (KO) mice. These mice recapitulate the features of human Ga 11 -driven melanomas. They developed neoplastic hyperpigmented melanocytic lesions in the uveal tract, skin, and leptomeninges. These mice developed lesions in the lung and lymph nodes. Deletion of Bap1 accelerated skin tumor growth and mouse mortality. The GNA11 Q209L , Bap1 loss tumors were resistant to the MEK inhibitor trametinib. To identify alternative therapeutic targets, we performed integrative analysis comparing BRAF mutant and Ga 11/q mutant human and murine cancers, and we identified a critical requirement of a Ras guanine exchange factor (GEF), RasGRP3, for Ga 11/q -mediated tumorigenesis. Figure S2A ). In vehicle-treated Tyr-CreER T2 -positive or tamoxifen-treated Tyr-CreER T2 -negative control mice, there was no discernible pathologic phenotype in the skin or the uveal tract up to 18 months ( Figures 1A, 1B , S2B, and S2C). In TyrCreER T2 ;GNA11 Q209L mice, pathological analysis of the skin 3 months post-induction showed extensive follicular and dermal melanocytic proliferation ( Figure 1C ), which progressed to melanomas encompassing the dermis and subcutaneous tissues in 50% of mice by 6 months after injection ( Figure 1D ). These proliferating melanocytes stained positive for a melanocyte cocktail ( Figure S2D ). Tumor cells contained abundant pale amphophilic cytoplasm and a small nuclear-to-cytoplasmic ratio ( Figure S2D ). For comparison, we also treated Tyr-CreER T2 ;BRaf CA/+ mice, which express the conditional BRaf V600E allele in melanocytes.
RESULTS

Melanocyte
We observed melanocytic hyperplasia without progression to melanoma up to 12 months post-induction, similar to previous observations ( Figure S2E ) (Dankort et al., 2009 Figure 1G , i and ii). These cells were positive for MITF and melanocyte cocktail staining ( Figure 1G , iii and iv). We further observed perineural spread of malignant melanoma to the optic nerve ( Figure 1H ). We next examined the effect of GNA11 Q209L in resident melanocytes of other organs, including the heart, harderian gland, and brain (Aoki et al., 2009) . Gross examination of the brain revealed focal pigmentation of the leptomeninges in 80% of mice ( Figure S3A ). Pathological evaluation of the CNS of the TyrCreER T2 ;GNA11 Q209L mice showed melanocytic proliferation in the leptomeninges at the base of the brain, around cranial nerve roots, and within the longitudinal fissure ( Figure 2A , ii-iv).
There was prominent melanocytic hyperplasia within the third ventricle ( Figure 2A , i and iv). Clinically, primary melanocytomas occasionally occur within the ventricular system of the CNS (Tandon et al., 2008) . There was invasion of melanocytes to the (E and F) H&E of eyes from GNA11 Q209L mice 3 months (E) or 6 months (F) post-induction.
(G) H&E (i), H&E with melanin bleaching (ii), MITF immunohistochemistry (IHC) using diaminobenzidine (DAB) (brown) (iii), and melanoma cocktail IHC using red chromogen (red) (iv) from a GNA11 Q209L mouse 6 months post-induction. High-magnification insets of top panels are shown in bottom panel.
(H) H&E of a selected eye (i) with melanocytic perineural invasion of the optic nerve (ii). See also Figures S1 and S2.
periventricular space, and one mouse exhibited invasion to the olfactory bulb ( Figure 2A , iv and v). We observed robust proliferation of resident melanocytes in the harderian gland (Figure 2A , arrow). Examining the melanocytes of the heart in GNA11 Q209L mice, we observed invasive neoplasms that infiltrated and thickened the tricuspid valve and infiltrated the myocardium of the right atrium and interventricular septum ( Figures 2B and 2C ). We suspect these lesions were primary tumors of the resident melanocytes of the heart. Melanocytic lesions were not evident in TyrCreER T2 ;BRaf CA/+ mice in these areas ( Figures S3C and S3D ).
In GNA11 Q209L mice, we observed multi-focal lesions in the lungs that may represent metastases, although we cannot rule out transformation of rare resident lung melanocytes ( Figures  2B, 2D , and 2E). However, the morphology of these lesions resembled the primary tumors ( Figures 1D, 1G , ii, 2B, and 2C). These lesions occurred early and were observed in mice with less advanced skin and uveal lesions ( Figure S3E ). We observed melanocytes infiltrating the lymphatic system, as visualized by MITF staining in the axillary lymph nodes (Figures 2F and 2G Recently, a mouse model harboring GNAQ Q209L was characterized (Huang et al., 2015) . When activated in melanoblasts during embryogenesis with Mitf-Cre, the mice exhibited UM, LMN, neoplastic melanocytic growth in the harderian glands, and rare lesions in the skin, as well as lymph nodes and lung (Huang et al., 2015) . Figure 3D ; p < 0.05), due to increased skin melanoma burden (Figures 3E and 3F) . The loss of Bap1 in these mice did not appreciably alter the size or incidence of uveal lesions, but it contributed to an increased progression to skin melanomas originating from the tail and ears ( Figures 3E-3G ). We confirmed Bap1 KO in uveal melanocytes using PCR ( Figure S4C ). Unlike in human UM patients, no pigmented liver lesions were observed ( Figures  S4D and S4E ). We observed no significant increase in the size or incidence of lung lesions in the absence of Bap1 . Histologically, GNA11 Q209L skin melanomas exhibited slender oval nuclei while GNA11 Q209L ;Bap1 KO had larger euchromatic nuclei ( Figure 3H ). GNA11 Q209L ;Bap1 KO skin melanomas exhibited a higher proliferation index (Figures 3H and 3I; p < 0.0001).
To determine the extent that Bap1 KO molecularly recapitulates human melanoma and to understand the Bap1-regulated transcriptional programs, we performed transcriptome analysis of mouse and human melanomas. RNA sequencing (RNA-seq) revealed the R26-GNA11 Q209L transcript level was 4-to 8-fold lower than endogenous murine Gnaq and Gna11 transcript levels, indicating modest expression of mutant GNA11 is required for tumorigenesis ( Figure S5A ). Analysis of RNA-seq of GNA11 Q209L and GNA11 Q209L ;Bap1 KO skin melanomas confirmed deletion of Bap1 ( Figure S5B ). Using a gene set comprised of genes upregulated in GNA11 Q209L ;Bap1 KO versus GNA11 Q209L skin melanomas (Mouse_Bap1KO_UP), we performed gene set enrichment analysis (GSEA) using The Cancer Genome Atlas (TCGA) UM dataset (Robertson et al., 2017) . This showed Mouse_Bap1KO_UP genes are significantly enriched among genes negatively correlated with BAP1 expression in UM, suggesting BAP1 deletion in skin melanomas of mice results in the upregulation of similar genes to human UM (Figure 3J ; Table S1 ). To explore the function of the shared genes, we performed functional annotation of the leading edge genes ( Figure 3J , red) that drove the GSEA enrichment. We found the most enriched gene ontology (GO) and Swiss-Prot (SP) pathways all involved cell cycle and mitosis ( Figure 3K ). In a complementary approach, we identified a UM primary tumor line, UPMM3, contained a frameshift deletion of BAP1 ( Figure S5C ) . We restored wild-type BAP1 ( Figure S5D ) and generated a gene expression profile using RNA-seq. As controls, we expressed BAP1 with mutations in the deubiquitinase domain (p.Cys91Trp, p.Ala95Pro) found in cancer (Harbour et al., 2010) as well as EGFP. Wild-type BAP1 restoration significantly changed gene expression while the presumably non-functional mutants did not, observed by gene hierarchical clustering ( Figure S5E ). We next performed GSEA, and we found the Mouse_Bap1KO_UP gene set was significantly enriched among genes downregulated in UPMM3 cells by BAP1 (wild-type [WT]) restoration ( Figure 3L ). Functional analysis of leading edge genes showed cell cycle pathways were enriched ( Figure 3M ). GSEA on three BAP1 datasets (mouse model, TCGA, and UPMM3) using the >8,300 gene sets from the Molecular Signatures Database (MSigDB) showed cell cycle and melanoma metastasis signatures are highly enriched in each (Table S1 ; Figures S5F and S5G). Therefore, in UM, the loss of Bap1 can promote aggressive disease with a propensity to proliferate and metastasize, consistent with clinical data implicating BAP1 loss as a poor prognostic biomarker.
Ga 11/q -Driven Cells Have Reduced Sensitivity to MEK Inhibition Activation of the Ga 11/q -PLCb pathway leads to downstream activation of the MAPK pathway. While preclinical data using UM cell lines suggest MEK inhibition may be a therapeutic strategy (Ambrosini et al., 2012) , a recent phase 3 study comparing selumetinib and chemotherapy failed to show significant improvement in progression-free or overall survival (Komatsubara et al., 2016) . Table S1 .
Prolonged selumetinib treatment induces RAF-MEK dimer formation, leading to reactivation of MAPK signaling, particularly in non-BRAF V600E -driven tumors. The newer MEK inhibitor trametinib uniquely decreases RAF-MEK interaction and MAPK reactivation (Lito et al., 2014) .
To address whether improved MEK inhibition can lead to therapeutic efficacy in UM, we utilized the GEMMs to perform in vivo trametinib treatment. We needed relevant control tumors that formed nodules of a similar size and were responsive to trametinib treatment. We observed Bap1 KO Figure 4D ).
However, GNA11 Q209L Bap1 KO tumors were resistant to trametinib treatment ( Figure 4D ). To determine if relative resistance to trametinib treatment was more generalized, we treated human BRAF V600E CM and Ga q/11 mutant UM cell lines with a clinically achievable concentration of trametinib (10 nM) (Infante et al., 2012) . Trametinib sustainably inhibited MAPK in CM cells. In UM cells, MEK phosphorylation was stable or increased over time and ERK phosphorylation was variably inhibited but rebounded by 24 hr ( Figure 4E ). This is consistent with known hypersensitivity of BRAF V600E melanoma to MEK inhibition (Solit et al., 2006) . Together, activating mutations in the Ga 11/q pathway exhibit in vivo and in vitro resistance to MEK inhibition. This highlights the need for novel therapeutic targets in UM.
Cross-Species Analysis Shows Ga 11/q -Driven Tumors Enforce a Melanocyte Lineage Program and Express High Levels of RASGRP3
To identify critical nodes in Ga 11/q -mediated tumorigenesis, we utilized a cross-species transcriptome analysis approach of human and murine melanoma. We sought to generate a transcriptional signature of Ga 11 -driven GEMM melanoma. We generated GEMM Figure 5A ).
Therefore, the oncogenic signaling driver, in addition to the location of the tumor, contributes to the oncogenic transcriptome. Functional annotation of the leading edge Ga 11/q signature genes showed upregulation of pigmentation and melanocyte differentiation pathways ( Figures 5B-5D ), consistent with the observation of highly pigmented melanomas in the GNA11 Q209L GEMM (Figures 1, 2, and 4). This is also consistent with the clinicopathological observations that metastatic UMs retain greater pigmentation than CMs (Rothermel et al., 2016) and with our previous observation that CYSLTR2 L129Q enforces a melanocyte lineage (Moore et al., 2016) . Further examination of top-ranked genes identified RASGRP3 as highly expressed in both Ga 11/q -mutated human and GEMM melanomas ( Figures 5E and 5F ). Pan-cancer analysis of RNAseq datasets from TCGA ( Figure 5E ) and Affymetrix U133Plus2 datasets curated by gene expression across normal and tumor tissue (GENT) ( Figure S6 ) showed RASGRP3 is expressed at significantly higher levels in UMs than in CMs and other cancer types. Notably, all TCGA UMs expressed high RASGRP3, and the five TCGA SKCMs with the highest RASGRP3 expression harbored either GNAQ or GNA11 mutations and either BAP1 loss (mutation or monosomy 3) or SF3B1 mutations, suggesting they may be malignant blue nevi (Griewank et al., 2017) (Figure 5E , circled). RASGRP3 encodes Ras guanyl-releasing protein 3 (RasGRP3), a GEF that promotes the release of GDP-bound Ras in order to bind GTP, yielding active Ras (Ras-GTP) (Rebhun et al., 2000) . RasGRP3 activation is dependent on both DAG binding and phosphorylation on Thr 133 by protein kinase C (PKC) (Aiba et al., 2004; Zheng et al., 2005) . Together, these signaling events place the activation of RasGRP3 downstream of UM-activating mutations (CYSLTR2, GNAQ, GNA11, and PLCB4), and they suggest RasGRP3 may be a key signaling node that can integrate the UM-activating mutations into the MAPK pathway.
To determine if RasGRP3 expression is retained in cell lines, we screened a panel of UM and CM cells, and we found RasGRP3 to be expressed exclusively in UM cells ( Figure 5G ).
RasGRP3 Is Required for Ras-MAPK Activation and Growth in UM Cells
To determine if RasGRP3 is required for Ga 11/q -mediated activation of the MAPK pathway and for growth in UM, we generated two short hairpin RNAs (shRNAs) to mediate knockdown of RASGRP3 (shRasGRP3-1 and shRasGRP3-2) and a control (shSCR). Depletion of RasGRP3 significantly reduced cell proliferation in GNA11 or GNAQ mutant cells ( Figures 6A and S7A ). In contrast, knockdown of RasGRP3 in CM cells did not (Figures 6B and S7A) .
We next sought to characterize the response of RasGRP3 depletion in the context of Ras activation and subsequent downstream MAPK signaling. We stably expressed two doxycycline (dox)-inducible RasGRP3 shRNAs (dox-shRasGRP3-1 and dox-shRasGRP3-2) and a dox-inducible control (dox-shSCR) in the panel of UM and CM cells. Depletion of RasGRP3 with dox significantly reduced the proportion of Ras-GTP and phosphorylation of ERK1/2 and P90 RSK in UM cells ( Figure 6C ). Consistent with the cellular growth data, there was no change in Ras activation or MAPK signaling upon depletion of RasGRP3 in CM cells ( Figure 6C ). To elucidate the requirement of the Ras GEF activity of RasGRP3, we examined if ectopic expression of KRAS G12V could rescue the proliferation and MAPK signaling in three UM cell lines depleted of RasGRP3. We performed growth competition assays in which we first generated cells where 20%-50% expressed KRAS G12V -IRES-GFP and empty vector at low MOI. We next infected these cells with shSCR or shRasGRP3, and we tracked the percentage of GFP-positive cells over time using fluorescence-activated cell sorting (FACS). The percentage of empty vector-expressing GFP-positive cells remained stable over time regardless of RasGRP3 depletion in both CM and UM cells ( Figure S7B ). In contrast, the percentage of KRAS G12V -expressing GFP-positive cells increased after RasGRP3 depletion compared to shSCR in all three UM lines ( Figure 6D ), indicating KRAS G12V conveys a growth advantage specifically after RasGRP3 depletion. Expression of KRAS G12V rescued the reduction in ERK phosphorylation observed upon depletion of RasGRP3 ( Figure 6E Figure S7D ). The difference in melanocyte lineage commitment between Ga 11/q and RAS/RAFdriven transformed melanocytes is consistent with observations in our GEMMs and patient tumors.
To determine the potential role of RasGRP3 in Ga 11/q -, BRAF-, and KRAS-mediated tumorigenesis, we performed shRNA-mediated knockdown of Rasgrp3 (shRasgrp3-1 and shRasgrp3-2). Knockdown of Rasgrp3 significantly reduced cell growth in GNAQ Q209L -dependent, but not in BRAF V600E -or KRAS G12V -dependent, melan-a cells (Figures 7A and S7E) . Depletion of Rasgrp3 in GNAQ Q209L melan-a cells reduced Ras-GTP and the phosphorylation of ERK and P90 RSK ( Figure 7B ). Therefore, RasGRP3 is specifically required for Ga 11/q -mediated oncogenic growth.
DISCUSSION
UMs, LMNs, and blue nevi harbor activating mutations along the CYSLTR2-Ga 11/q -PLCb pathway, and they can have mutually 
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Luminesence ( , 2016) . This distinct molecular profile is observed in a small subset of CMs and $10% of mucosal melanomas (Sheng et al., 2016) . Pathologically, UMs are characterized by their retention of the melanocyte lineage program, including pigmentation (Rothermel et al., 2016) . No proven effective therapies exist for UM. As with Ras, it is difficult to target G-proteins with competitive inhibitors to the nucleotide-binding site due to the high cellular concentrations of GTP. Since Ga 11/q signaling activates PKC and the MAPK pathway, via PLCb, many groups have studied the role of PKC and MAPK in UM. Cells with Ga 11/q mutations were modestly sensitive to MEK inhibition and combination treatment of PKC and MEK inhibitors (Chen et al., 2014) . Unfortunately, PKC targeting is limited by toxicity, and a completed phase 3 trial with selumetinib showed no clinical benefit (Komatsubara et al., 2016) . In addition to PLCb, Ga q directly interacts with the Trio family of Rho-GEFs (Trio, p63-RhoGEF, and Kalirin) to activate Rac and Rho and downstream YAP, and this pathway may represent a therapeutic target (Feng et al., 2014; Yu et al., 2014) . Another promising target is ARF6, a GTPase involved in vesicle trafficking and required for proper shuttling of activated Ga q to cytoplasmic vesicles, where downstream signaling to both PLCb and Rho were localized (Yoo et al., 2016) . In addition to Ga 11/q signaling, another therapeutic strategy is targeting the melanocyte lineage. IMCgp100 is a bispecific antibody that binds gp100 (PMEL) on tumor cells and CD3 on T cells (Carvajal et al., 2014, J. Stem Cell Res. Ther., abstract) . A phase 1 trial in melanoma showed a disease control rate of 21% and 57% in CM and UM, respectively, and an expanded study in UM showed a similar disease control rate with some durable responses (Iams et al., 2017 (Dankort et al., 2009 ) and in a transgenic mouse of Tyr-driven SV40 T-antigen , one limitation in our mouse model was the inability to specifically activate GNA11 Q209L in defined melanocytic subsets, and this hampers the ability to definitively assign metastasis (Gibson et al., 2010; Klein-Szanto et al., 1991) . GNA11 Q209L -driven tumors were highly pigmented compared to BRaf V600E , consistent with clinical observation that Ga 11/qdriven primary blue nevi, UM, and UM metastases retain pigmentation (Emley et al., 2011; Rothermel et al., 2016) . Therefore, Ga q/11 signaling drives lineage commitment, and targeting the lineage, such as IMCgp100, is a promising therapeutic strategy (Carvajal et al., 2014, J. Stem Cell Res. Ther., abstract) . Bap1 loss in our GEMM accelerated skin melanoma growth, consistent with the clinical observation that BAP1 loss is found in transformed, but not benign, blue nevi (Griewank et al., 2017 ). Yet, there was no significant change of uveal pathology, highlighting a limitation of our model. Cross-species comparison between representative GEMM models with human disease can identify critical mediators of tumorigenesis (Johnson et al., 2010) . By cross-referencing the RNA-seq data from the GEMM and human disease data, we identified a Ras-GEF, RasGRP3, as a required signaling node for UM. Consistent with a recently published study (Chen et al., 2017) , we observed RasGRP3 is highly upregulated in UM and is required for proliferation. We additionally showed engineered cells driven by mutant Ga 11/q specifically require RasGRP3 for Ras activation and growth. RASGPR3 expression is tissue specific and, among cancers, constrained to Ga 11/q -driven melanomas, leukemias, and lymphomas, suggesting RasGRP3 is a specific vulnerability in Ga 11/q -driven tumors and potentially a therapeutic target. The interaction between G-proteins and their GEFs is a viable drug target, as exemplified by the antibiotic brefeldin A, which blocks interaction between ARF1 and its GEF Sec7 (Mossessova et al., 2003) , and RasGRP3 may be similarly targeted.
EXPERIMENTAL PROCEDURES
Further details and an outline of the resources used in this work can be found in the Supplemental Experimental Procedures.
Mouse Experiments
All animal studies were performed in accordance with the MSKCC IACUC (11-12-029 were administered with intraperitoneal tamoxifen at 4 weeks of age with no regard to the sex of the animals, and histology was similar between males and females. Mice developed tumors in situ after tamoxifen injection. Mice were euthanized in response but not limited to the following: tumors larger than 1 cm 3 , tumor ulceration, tumors located too close to the trunk of the mice to impede movement and blood flow, and tumor burden, and time of euthanization was used for Kaplan-Meier survival analysis. For allograft studies, GEMMderived tumors were grafted into 6-to 8-week-old female CB17-SCID mice and treated with vehicle or trametinib via oral gavage.
Histology, Immunohistochemistry, and Immunofluorescence All tissues were fixed at 4 C overnight in 4% paraformaldehyde. Tissue processing, embedding, sectioning, H&E staining, and H&E staining with melanin bleaching were performed by Histoserv. Skull sections were performed following decalcification.
RNA-Seq
Total RNA was extracted from fresh-frozen tissue or cell lines using QIAGEN's RNeasy Mini Kit. The isolated RNA was processed for RNA-seq by the Integrated Genomics Core Facility at MSKCC.
Cell Lines
Melan-a cells were provided by D. Bennett (Bennett et al., 1987) ; MEL202, MEL270, OMM1.3, COLO800, UPMM3, A375, and A2058 cells were submitted for short tandem repeat (STR) profiling and MSK-IMPACT (integration mutation profiling of actionable cancer targets) for mutational status at MSKCC to confirm their authenticity.
Statistics
Boxplots represent 25th and 75th percentiles with midline indicating the median; whiskers extend to the lowest/highest value within 1.5 times the interquartile range. Outliers are shown as dots. Comparisons for growth curves and xenograft experiments between two groups were performed using a two-tailed parametric unpaired t test. All statistics were performed using GraphPad Prism 6.0 software.
DATA AND SOFTWARE AVAILABILITY
The accession number for the data reported in this paper is GEO: GSE97225. 
SUPPLEMENTAL INFORMATION
SUPPLEMENTAL EXPERIMENTAL PROCEDURES Genetically Engineered Mice
We cloned in human GNA11 Q209L with an internal glu-glu tag into a modified pBTG (Murtaugh et al., 2003) (Addgene plasmid 268) with LoxP sites reversed to remove the forward ATG codon within LoxP site and into Rosa26 locus as previously described (Addgene 15036) (Chen et al., 2013) .
Gene targeting was performed at the Rockefeller University Gene Targeting Resource Center (Head: Chingwen Yang). The targeting plasmid was electrophoresed into albino C57BL/6J ES cells and G418 resistant clones were isolated by standard procedures. The clones were screened by Southern blotting. Two positive clones were injected into C57BL/6J blastocysts by the MSKCC Mouse Genetics Core Facility (Head: Willie Mark) and chimeras were mated with albino C57BL/6J females. Germline transmission was confirmed in albino offspring using Southern blotting. For subsequent generations, GNA11 Q209L mouse genotyping was performed by qPCR of genomic DNA using primers listed in Table  S2 . Table S2 .
Mouse survival was determined under the recommendation of MSKCC veterinary services or upon encountering mice undergoing visible discomfort and in accordance to the MSKCC Institutional Animal Care and Use Committee (IACUC 11-12-029). In accordance to our animal protocol, mice were euthanized in response but not limited to the following: tumors larger than 1cm 3 , tumor ulceration, tumors located too close to the trunk of the mice to impeded movement and blood flow and tumor burden.
Intraperitoneal injection of tamoxifen was performed at 4-weeks of age with no regard to the sex of the animals and histology was similar between both males and females.
Allograft and Treatment
Tumors from Tyr-CreER T2 ;Braf
V600E
;Bap1 KO and Tyr-CreER T2 ;GNA11
Q209L
;Bap1 KO mice were expanded in 6-8 week old C.B17-scid mice (C.B-Igh-1 b /IcrTac-Prkdc scid ; Taconic) and then serial grafted bilaterally using equal size tumors. The experimental cohort of mice 6-8 week old female C.B17-scid mice (Taconic) of 8 tumors for the vehicle and trametinib treated Tyr-CreER T2 ;GNA11
;Bap1 KO and 24 tumors for the trametinib treated arm and 7 tumors for the control arm for Tyr-CreER T2 ;Braf
V600E
;Bap1 KO tumors. The size of each cohort was determined on the basis of previous experiments without specific statistical methods. Mice we treated with 3mg kg -1 trametinib (Active Biochem) dissolved in trametinib solvent (30% PEG-400, 0.5% TWEEN® 80, 5% propylene glycol in PBS) once daily for 5 days a week. Tumors were measured with calipers every 2 or 3 days for up to 25 days with trametinib treatment and were actively measured for at least 10 days before treatment. Tumor growth curves were visualized with Prism GraphPad 6.0. Tumor volume was calculated using the formula: volume = ( ℎ)( ℎ)(ℎ ℎ ) 6 .
Histology and immunohistochemistry
Prior to immunohistochemistry, melanin bleaching was performed using a delicate melanin bleach kit (Polysciences Inc.) according to the manufacturer's instructions. Immunohistochemistry for HMB45, DT101, BC199 melanoma cocktail (Abcam, ab732, 1:50), MITF (Cell Signaling Technology, 12590, 1:50), Ki-67 (Abcam, ab16667, 1:100) antibodies were diluted in SignalStain antibody diluent (Cell Signaling Technology). Staining was performed using a standard multimer/diaminobenzidine (DAB) detection protocol for MITF and Ki67 and red chromogen staining (alkaline phosphatase; Ventana; UltraMap Red) for the melanoma cocktail following epitope retrieval with citrate (Ventana; CC1), hematoxylin counterstain on a Discovery Ultra system (Roche/Ventana) with appropriate negative and positive controls. Immunohistochemistry for each tissue shown was preformed on tissues harvested from at least 5 animals.
Immunofluorescence of eye and skin
All tissues were fixed at room temperature for 30min in 4% paraformaldehyde (Electron Microscopy Sciences). Tissues were then incubated in 30% sucrose in PBS at 4C overnight, washed once with PBS, embed in OCT, flash frozen and cut into 5 µM sections using a cryostat. Tissue sections were blocked for 1 hour using 5% goat serum, incubated with Gp100 antibody at 4 °C overnight and secondary antibody for 2 hours at room temperature. Slides were mounted using PBS with 1ug ml -1 DAPI for direct visualization of YFP and Gp100. Images were taken on a Nikon Eclipse TE2000-E microscope using a Photometric Coolsnap HQ camera. Images were taken with ×20 (numerical aperture 0.75) objectives. Monochrome images taken with DAPI, YFP and Texas Red filter sets were pseudo-colored blue, green and red, respectively, and merged using ImageJ.
Intraperitoneal injection of tamoxifen was administered in both sexes of the animals and histology was similar between both males and females. At least 45 animals for each genotype (GNA11 
RNA-seq
For mouse tumors, total RNA was extracted from fresh-frozen tissue or cell lines using Qiagen's RNeasy Mini Kit (Qiagen). The isolated RNA was processed for RNA-sequencing by the Integrated Genomics Core Facility at MSKCC. The libraries were sequenced on an Illumina HiSeq-2500 platform with 51 bp paired-end reads to obtain a minimum yield of 40 million reads per sample. The sequence data were mapped to the mouse reference genome (mm9) and the number of reads was quantified using STAR v2.330 (Dobin et al., 2013) .
For UPMM3 cells, the libraries were sequenced on an Illumina HiSeq-2500 platform with 51 bp singleend reads to obtain a minimum yield of 40 million reads per sample. The sequence data were mapped to the human reference genome (hg19) and the number of reads was quantified using Cufflinks (Roberts et al., 2011) . GSEA was performed using JAVA GSEA 2.0 program (Subramanian et al., 2005) . The gene sets used for analysis were the Broad Molecular Signatures Database gene sets c2 (curated gene sets), c5 (gene ontology gene sets), c6 (oncogenic signatures). GSEA enrichment sets are shown in Table S1 .
Level 3 RNA-seqV2 data for TCGA uveal melanoma (n=80) and cutaneous melanoma (SKCM; n=471) were downloaded from NIH TCGA server. We merged the samples and annotated them by mutational status (BRAF V600E , GNAQ or GNA11 at R183 or Q209) and by tissue source (primary or metastatic). Differential gene expression was performed using ANOVA analysis with the Partek Genomics Suite 6.6 in both the TCGA and genetically engineered mouse model datasets. Expression of RASGRP3 from pan-TCGA cancers was downloaded from cBioportal (Cerami et al., 2012) and from Gene Expression across Normal and Tumor tissue (GENT) (Shin et al., 2011) was downloaded from http://medicalgenome.kribb.re.kr/GENT/.
Ki-67 quantification
Following immunohistochemistry for Ki-67, 10 randomly selected field images at 40 x magnifications were taken. These images were converted to greyscale, threshold adjusted, and particles were analyzed using ImageJ v1.60 (NIH) automated counting to determine the number of cells per field. The same parameters were used throughout quantification. To determine the percent of cells that were positive for Ki-67, we performed identical procedures while optimizing the threshold to include only cells with positive DAB staining. The same parameters were used throughout quantification.
PCR for Bap1 lox/lox excision
DNA from Bap1 mice was isolated using DNeasy Blood & Tissue Kit (Qiagen). DNA from whole cutaneous tumors and dissected uveal tracts were used for the PCR. Control tissues were isolated from mouse toes. PCR of genomic DNA was performed using primers listed in Table S2 .
Cell lines
Melan-a cells were provided by D. Bennett (St. George's Hospital, University of London, London, UK) (Bennett et al., 1987) and KRAS G12V were propagated in the absence of TPA. MEL202, MEL270, OMM1.3, COLO800 cells were grown in RPMI. UPMD1, UPMD2 and UPMM3 cells were grown in Ham's F12 media. A375 and A2058 cells were grown in DMEM media. 293T cells were used for retrovirus and lentivirus production and maintained in DMEM media. All cell culture media contained 10% FBS, penicillin (100 U ml -1 ), streptomycin (100 μg ml -1 ), L-glutamine (2mM). All cells were grown in a humidified incubator at 37 °C with 5% CO2 and were tested regularly for mycoplasma contamination. All cell lines used were negative for mycoplasma. All uveal melanoma cell lines were validated for mutations status by MSK-IMPACT.
Proliferation and survival assays
Growth curves were performed following shRNA infection and around 1,000-3,000 cells were plated in a 96-well plate 24 hours following infection. Every 48 hours following infection, the number of cells was determined using a CelltiterGlo assay (Promega). IC50 assays were performed by plating 1,000-3,000 cells in a 96-well plate, allowed to adhere overnight, and then incubated with either fresh media containing trametinib. After 5 days, the number of cells was determined using a CelltiterGlo assay. Representative experiments are shown. Cell growth was assessed in three independent experiments, each in quadruplet.
Immunoblotting
Whole cell lysates were prepared in cell lysis buffer (Cell Signaling Technology) containing freshly added protease and phosphatase inhibitors (PhosSTOP, Roche, cOmplete EDTA-Free, Roche). Tumor lysates were generated by homogenization of flash-frozen tissue in cell lysis buffer (Cell Signaling Technology) containing freshly added protease and phosphatase inhibitors (PhosSTOP, Roche, cOmplete EDTA-Free, Roche). Equal amounts of protein, as measured by BCA protein assay (Thermo Scientific), were resolved on NuPAGE Novex 4-12% Bis-Tris Protein Gels (Life Technologies) and transferred electrophoretically onto a 0.45µm nitrocellulose membrane (Bio-Rad). Membranes were blocked for 1 hour at room temperature in StartingBlock TBS (Thermo Scientific) or Odyssey blocking buffer (LI-COR) before being incubated overnight at 4°C with the primary antibodies diluted at 1:1000 unless otherwise noted in either StartingBlock or Odyssey blocking buffer. The following primary antibodies were used (Cell Signaling unless noted otherwise): phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204; 4370), p44/42 MAPK (Erk1/2;4695), phospho-P90 RSK (Ser380;12032), RSK1/2/3 (9355), RasGRP3 (3334), Ras (8832), CyclinD1 (2922), SPRY4 (Santa Cruz Biotechnology; sc-30051), BAP1 (Santa Cruz Biotechnology; sc-28383), HA-tag (Roche; 3F10), GNAQ (abcam; ab199533), GAPDH (1:5,000 dilution; Applied Biological Materials, G041), β-actin (1:5,000 dilution; abcam, AC15). The Ras-GTP assay was performed according to manufactures instructions (Cell Signaling; 8821).
shRNA and inhibitors
For shRNA mediated knockdown of RASGRP3 the following hairpins were used with sequences listed in Table S3 . Human shRASGRP3-1 and shRASGRP3-2 were obtained from the MSKCC RNAi Core in pLKO.1 and were subcloned into Tet-pLKO-puro (Wiederschain et al., 2009 ) (Addgene plasmid 21915 ). Mouse shRasgrp3-1 and shRasgrp3-2 were obtained from the MSKCC RNAi Core in pLKO.1. Stable expressing Tet-ON shRasGRP3 were induced with doxycycline 1µg ml -1 (Research Products International) and cells were harvested for protein 72 hours post-doxycycline addition. Melan-a cells were treated with the indicated dose of trametinib (SelleckChem). Cell growth for the half-maximal inhibitory concentration (IC50) was assessed using CellTiter-Glo (Promega) five days post trametinib treatment.
Exogenous gene expression
Melan-a cells were stably transduced with: BRAF V600E, MSCV-HA-FLAG-BRAF-V600E. MSCV-HA-FLAG-V600E was cloned using the gateway method using pDONOR-BRAF (Addgene plasmid 70300) and subcloned into MSCV-HA-FLAG-puro-Dest. Site directed mutagenesis was performed using QuikChange (Agilent) to wild-type BRAF to introduce a p.Val600Glu mutation to give BRAF ; CAG-LSL-EYFP and control Cre-negative; CAG-LSL-EYFP mice 7 days after tamoxifen injection. Melanocytes are marked by Gp100-positivity as well as strong pigment readily appreciable on bright-field.
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